Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective

Drugs and Aging

Volumn 10, Issue 2, 1997, Pages 107-118

  Eri, Lars M ^a   Tveter, Kjell J ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE;

AGE; ASTHENIA; DRUG CHOICE; DRUG EFFICACY; HEALTH CARE COST; HUMAN; IMPOTENCE; LONG TERM CARE; MALE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; PHARMACOECONOMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SYMPTOM; VERTIGO;

EID: 0031046447     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710020-00004     Document Type: Review

References (84)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 39-48
3. Glynn RJ, Campion EW, Bouchard GR, et al. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 1985; 121: 78-90
4. Arrighi HM, Metter KJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38 Suppl. 1: 4-8
5. Jensen KM-E, Jørgensen JB, Mogensen P, et al. Some clinical aspects of uroflowmetry in elderly males: a population survey. Scand J Urol Nephrol 1986; 20: 93-9
6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
7. Jolleys JV, Donovan JL, Nanchahal K, et al. Urinary symptoms in the community: how bothersome are they? Br J Urol 1994; 74: 551-5
8. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989; 2: 69-77
9. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism'. BMJ 1994; 308: 929-30
10. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600
11. Sagnier P-P, Girman CJ, Garraway M, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15-20
12. Moon TD, Brannan W, Stone NN, et al. Effect of age, educational status, ethnicity and geographic location on prostate symptom scores. J Urol 1994; 152: 1498-1500
13. Boyle P, Maisonneuve P, Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996; 155: 176-80
14. Ekman P. BPH epidemiology and risk factors. Prostate 1989; 2 Suppl. 2: 23-31
15. Graversen PH, Gasser TC, Wasson JH. Controversies about indications for transurethral resection of the prostate. J Urol 1989; 141: 475-81
16. Barry MJ, Fowler FJ, O'Leary MP, et al. The measurement committee of the American Urological Association: the American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57
17. 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822-5
18. Guess HA, Jacobsen SJ, Girman CJ, et al. The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia. Med Care 1995; 33: AS26-35
19. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-7
20. Schatzl G, Madersbacher S, Marberger M. The postoperative morbidity of transurethral resection of the prostate (TUR/P) and of four minimally invasive treatment alternatives [abstract no. 389]. J Urol 1996; 155: 408A
21. Kaplan SA. Benign prostatic hyperplasia - are we too 'hot' on new therapies? [editorial] J Urol 1996; 156: 426-7
22. Rittmaster RS, Finasteride. N Engl J Med 1994; 330: 120-5
23. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasicride. Eur Urol 1995; 27: 267-73
24. McConnell JD, for the Benign Proslatic Hyperplasia Guideline Panel. Clinical practice guidelines: quick reference guide for clinicians. Benign prostatic hyperplasia: diagnosis and treatment. Am J Fam Phys 1994; 49: 1157-65
25. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
26. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of benign prostatic hyperpla-sia in the United States. J Urol 1995; 154: 205-6
27. Janknegt RA. Summary: perspectives on the management of benign prostatic hyperplasia. Scand J Urol Nephrol 1995; 29: 35-6
28. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
29. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271-7
30. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46: 177-208
31. Yu H-J, Chiu T-Y, Lai M-K. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. J Formos Med Assoc 1995; 94: 37-41
32. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment of benign prostatic hyperplasia: a urodynamic evaluation. Br J Urol 1992; 70: 65-72
33. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91
34. Stoner E, and the Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-9
35. Lepor H, Wiliford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-9
36. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-7
37. Lepor H. Long-term evaluation of tamsulosin, a prostate selective alphal antagonist [abstract no. 1099]. J Urol 1996; 155: 585A
38. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
39. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol 1995; 28: 304-9
40. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
41. Walsh PC. Treatment of benign prostatic hyperplasia [editorial]. N Engl J Med 1996; 335: 586-7
42. Monda JM, Oesterling JE. Subspecialty clinics: urology. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc 1993; 68: 670-9
43. Fabricius PG, Weizert P, Dunzendorfer U, et al. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Proslate Suppl 1990; 3: 85-93
44. Thomas S. for the ITT Study Group. The international terazosin trial (ITT) - a double-blind, placebo-controlled randomized withdrawal study of the symptomatic treatment of BPH [abstract no. 236]. Proceedings of the 11th Congress of the European Association of Urology. Berlin 1994 Jul 13-16: 124
45. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599-604
46. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
47. Lepor H, on behalf of the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13
48. Kane MM, Fields DW, Vaughan Jr ED. Medical management of benign prostatic hyperplasia. Urology 1990; 36: 5-12
49. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign proslatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307
50. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995; 45: 258-64
51. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779-82
52. Jønler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66-81
53. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7
54. Guess HA, Gormley GJ, Stoner E, et al. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3-9
55. Williford WO, Lepor H, Dixon CM, et al. Serum PSA levels after 5 weeks of therapy with finasteride, terazosin, combination, and placebo: results of the VA Cooperative Study #359 [abstract no. 890]. J Urol 1996; 155: 533A
56. Abbou CC, Hozneck A, McCarthy C. Alfuzosin, a uroselective α1 blocker, versus pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH) [abstract no. 241]. Eur Urol 1996; 30 Suppl. 2: 77
57. Carraro JC, Raynaud JP, Chisholm GD. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients [abstract no. 240]. Eur Urol 1996; 30 Suppl. 2: 76
58. Plosker GL, Brogden RN. Serenoa repens (Permixon®): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996 Nov; 9: 379-95
59. Stoner E, on behalf of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-94
60. 1A-adrenoceptor antagonist: analysis of a multinational, mullicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145-54
61. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 29: 7-12
62. Lowe F, Tuttle J, Marks S, et al. Blood pressure effects of men with prostatism concurrently treated with antihypertensives and terazosin [abstract no. 176]. J Urol 1995; 153: 272A
63. Titmarsh S, Monk P. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987; 33: 460-77
64. Ahlstrand C, Carlsson P, Jönsson B. Estimated total costs of treating benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1995; 29: 57-63
65. Carson CC, Singla A, Rutledge R. Benign prostatic hyperplasia, impact of medical therapy on TURP: a statewide population-based analysis of 26625 patients [abstract no. 1481]. J Urol 1996; 155: 681A
66. Holtgrewe HE, Ackermann R, Bay-Nielsen H, et al. The economics of BPH. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27-30; Paris. Jersey: Scientific Communication International Ltd. 1993: 37-45
67. Hill SJ, Lawrence SL, Lepor H. New use for alpha-blockers: benign prostatic hyperplasia. Am Fam Physician 1994; 49: 1885-8
68. Gibbons RP, McNicholas TA, Koshiba K, et al. Surgical and laser treatment. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27-30; Paris. Jersey: Scientific Communication International Ltd, 1993: 363-76
69. Altwein JE. Introduction: the changing therapy of benign prostatic hyperplasia. Scand J Urol Nephrol 1995; 29: 1-6
70. Weis KA, Epstein RS, Huse DM, et al. The cost of prostatectomy for benign prostatic hyperplasia. Prostate 1993; 22: 225-34
71. Russell DJ, Kaufman Jr RP, Cain MP. Medical management of benign prostatic hyperplasia (BPH) versus transurethral prostatectomy: the economic consequences [abstract no. 883]. J Urol 1993; 149: 433A
72. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. In: Lepor H, Lawson RK, editors. Prostate diseases. Philadelphia: WB Saunders, 1993: 170-81
73. Naslund MJ, Stitcher MF. Cost comparison of medical management and surgical prostatectomy for BPH [abstract no. 161]. J Urol 1994; 151: 268A
74. Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169-78
75. Naslund MJ. A new valuation model for BPH treatment from the employer and patient perspective [abstract no. 1483]. J Urol 1996; 155: 682A
76. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol 1994; 151: 1-4
77. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311-16
78. Holtgrewe HL. Economics of benign prostatic hyperplasia. In: Kirby R, editor. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media, 1996: 527-36
79. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995; 155: 477-81
80. Lukacs B, McCarthy C, Thibault P. Twelve month assessment of long term health related quality of life (HRQOL) of 5849 patients suffering from benign prostatic hypertrophy (BPH) treated by an uroselective alpha 1 blocker alfuzosin [abstract no. 163]. J Urol 1994; 151: 268A
81. Martelli A, Pacifico P, Casadei B, on behalf of the Italian Alfuzosin Co-Operative Group. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Eur Urol 1993; 24 Suppl. 1: 28-33
82. Hillman AL, Schwartz JS, Willian MK, et al. The Hytrin community assessment trial (HYCAT): a randomized, placebo-controlled trial of the cost-effectiveness of Hytrin in the treatment of benign prostatic hyperplasia (BPH) (abstract no. 996]. J Urol 1995; 153: 477A
83. Khoury S. Future directions in the management of benign prostatic hyperplasia. Br J Urol 1992; 70 Suppl. 1: 27-32
84. Robert M, Costa P, Bressolle F, et al. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol 1995; 75: 317-24